DepoMed, Inc. (NASDAQ:DEPO)

CAPS Rating: 4 out of 5

A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.

Recs

0
Player Avatar Biotoday (31.51) Submitted: 10/7/2010 3:42:17 PM : Outperform Start Price: $4.62 DEPO Score: +4.84

On the verge

Featured Broker Partners


Advertisement